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Background: Thiazolidinone, has been employed in the preparation of different important drugs required for treatment
of inflammations, bacterial infections, and hypertension. Mannich bases have been shown to exhibit diverse biological
activities, such as antibacterial, and antifungal activities. Spiroheterocycles including thiazolidine moiety have
antimicrobial activity.
Results: In this study, a novel, rapid, and efficient protocol is developed for the synthesis of various 2-arylidine-1-thia-4-
azaspiro[4.5]decan-3-ones using sodium dodecylbenzene sulfonate (DBSNa) as an inexpensive and readily available
reagent in acetic acid at room temperature. High yields, easy work-up, and short reaction times are advantages of this
procedure. The synthesized arylidines were undergone Mannich reaction with formaldehyde and secondary amines in
absolute ethanol at room temperature to afford the corresponding N-Mannich bases. All prepared Mannich bases were
evaluated for their antimicrobial activity.
Conclusions: Good activity was noted for Mannich bases from 2-arylidine-1-thia-4-azaspiro[4.5]decan-3-ones, with some
members recorded higher antimicrobial activity.
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basesBackground
There are many bioactive molecules which possess vari-
ous heteroatoms such as nitrogen, sulfur and oxygen, al-
ways taken the attention of chemists over the years
mainly because of their biological significance. Thiazoli-
dinones are thiazolidine derivatives which have a sulfur
atom at position 1, a nitrogen atom at position 3 and a
carbonyl group at position 2, 4, or 5 [1], is considered as
an important biologically active scaffold that possesses
almost all types of biological activities [2]. This het-
erocyclic system has been employed in the preparation
of different important drugs required for treatment of
inflammations [3], bacterial infections [4], and hyper-
tension [5]. Some of the thiazole analogues are used as* Correspondence: essam.hussein78@yahoo.com
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unless otherwise stated.fungicides, inhibiting in vivo the growth of xanthomo-
nas and as ingredients of herbicides, antischistosomi-
cidal, and anthelmintic drugs [6]. Mannich bases are
reported to show a diversity of biological activities,
such as antibacterial [7,8], antifungal [9,10] activities.
Spiro derivatives have antibacterial, anticancer, and
anticonvulsants activities. Spiro heterocycles were
used as nitric oxide synthesis inhibitors [11] and po-
tential topical agents for vaginal infection [12]. Spiro
heterocyclic compounds including thiazolidine moiety
have antimicrobial activity [13].
In this paper and as a consequence of our previous
work on the synthesis of N-heterocyclic compounds
[14–18], and bioactive heterocyclic agents [19–21], we
reported herein an efficient protocol to the synthesis of
N-Mannich bases (6a-r) from 2-arylidine-1-thia-4-azas-
piro[4.5]decan-3-ones (5a-f ). The anti-microbial activity
of the prepared compounds (6a-r) was screened.is an Open Access article distributed under the terms of the Creative Commons
org/licenses/by/4.0), which permits unrestricted use, distribution, and
riginal work is properly credited. The Creative Commons Public Domain
rg/publicdomain/zero/1.0/) applies to the data made available in this article,
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Chemistry
First of all, 1-thia-4-azaspiro[4.5]decan-3-one (3) was
prepared via the three component cyclocondensation re-
action of cyclohexanone, thioglycolic acid, and ammo-
nium carbonate according to the previously reported
procedure [22] as shown in Scheme 1.Synthesis of 2-arylidine-1-thia-4-azaspiro[4.5]decan-3-ones
(5a-f)
In the first part of our research, we investigated a novel,
rapid and efficient protocol that was developed for the
synthesis of some 2-arylidine-1-thia-4-azaspiro[4.5]decan-
3-ones (5a–f) by the condensation of 1-thia-4-azaspir-
o[4.5]decan-3-one (3) with aromatic aldehydes (4a–f) using
sodium dodecylbenzene sulfonate (DBSNa) (20 mol %) in
acetic acid at room temperature as shown in Scheme 2 and
Table 1.
To find out the suitable conditions for the synthesis of
2-arylidine-1-thia-4-azaspiro[4.5]decan-3-ones, a series
of experiments were performed with the standard reac-
tion of 1-thia-4-azaspiro[4.5]decan-3-one (3) and benzal-
dehyde (4a) as a model reaction (Scheme 3, Table 2).
Effect of the reaction conditions In our initial study,
we tried to optimize the model procedure mentioned
above by detecting the efficiency of different reaction con-
ditions, such as piperidine/EtOH, p-TSA/EtOH, AcOH/
EtOH, AcONa/AcOH, H2SO4/AcOH, DBSNa/MeOH,
DBSNa/EtOH, DBSNa/H2O, DBSNa/AcOH (Table 2).
In each case, the reactants (10 mmol) were allowed to-
gether in 10 mL solvent at room temperature. In the
case of piperidine/EtOH, p-TSA/EtOH, AcOH/EtOH,
and AcONa/AcOH, the reaction proceeded with com-
paratively longer reaction time and poor reaction yield
(Table 2, entries 1–4). Acetic acid acidified with a drop
of H2SO4 can push the reaction towards the formation
of product in yields of 61% (Table 2, entry 5).
In the presence of sodium dodecylbenzene sulfonate
(DBSNa), the reaction was possible and the product (5a)
was obtained in good yields.
Sodium dodecylbenzene sulfonate was used in differ-
ent reaction media such as ethanol, methanol, water, and
acetic acid (Table 2, entries 6–9). The best results were
obtained when DBSNa was used as catalyst in acetic acidScheme 1 Synthesis of 1-thia-4-azaspiro[4.5]decan-3-one (3).as reaction medium, which provided a yield of 94%
(Table 2, entry 8).
Unfortunately, when the reaction was performed in
water, the yield of the desired product was obtained in a
trace amount (Table 2, entry 9).Evaluation of catalytic activity of DBSNa To deter-
mine the appropriate concentration of the catalyst used,
we investigated the model reaction at different concen-
trations of DBSNa (5, 10, 15, 20, and 25 mol %). It was
found that when the amount of DBSNa was increased
from 5 to 20 mol%, the yield increased from 68 to 94%,
respectively. However, there was no significant change in
reaction yield when the amount of catalyst was increased
further, to 25 mol%. Thus, 20 mol% DBSNa in acetic
acid is sufficient to push this reaction forward (Table 3).Synthesis of Mannich bases of 2-arylidine-1-thia-4-
azaspiro[4.5]decan-3-ones (6a-r)
The second part of the research includes the prepar-
ation of a series of Mannich bases (6a-r) in good yield
(71-91%) by the reaction of 2-arylidine-1-thia-4-azas-
piro[4.5]decan-3-ones (5a–f ) with formaldehyde and
secondary amines (piperidine, morpholine, and pyrroli-
dine) in absolute ethanol at room temperature for 1.5-
4 h (Scheme 4 and Table 4).
The structures of the isolated new products (6a-r)
were deduced by analyzing their physical and spectro-
scopic data, such as the data obtained using IR, 1H
NMR, and 13C NMR spectroscopy.
Taking (6b) as an example, the IR spectrum showed
the lack of the absorption band corresponding to NH
group. The 1H NMR spectrum showed the presence of a
singlet signal at δ = 4.15 ppm for the methylene protons
and two triplet signals at 2.47, 3.59, ppm for morpholine
ring protons.
Antimicrobial activity
In vitro antibacterial activity
The synthesized compounds (6a-r) were screened in vitro
for their antibacterial at 50 mg/mL concentration against
Staphylococcus aureus as Gram positive bacteria, Escheri-
chia Coli, Pseudomonas aeroginosa as Gram negative bac-
teria using Ciprofloxacin as standard antibacterial reference.
Scheme 2 Synthesis of 2-arylidine-1-thia-4-azaspiro[4.5]decan-3-ones (5a-f).
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ial activities with respect to the reference drug.
The results obtained in Table 5 indicated that the type
of substituents (Ar) and (R) are the controlling factors in
developing the total antibacterial properties of the tested
Mannich bases (6a-r).
Data in Table 5 revealed that compounds 6e, 6 h, 6 k,
6 m, 6n, 6p and 6q, have superior significant antibacterial
potency. Compounds 6n and 6q [Ar = 4-MeOC6H4 and 4-
pyridyl; R =morpholin-1-yl] have excellent activities against
Gram positive bacteria (Staphylococcus aureus) and Gram-
negative bacteria (Escherichia Coli and Pseudomonas aero-
ginosa). Compound 6p [Ar = 4-pyridyl; R = piperidin-1-yl]
has excellent potency against Staphylococcus aureus, mod-
erate activity against Pseudomonas aeroginosa, and poor
activity against Escherichia Coli. Structure-Activity relation-
ships (SAR) based on the obtained results indicated that
the best observed antibacterial activity is that which Ar is
phenyl ring attached with electron donating function
(MeO) as exhibit in compound 6n. However, substituting
the phenyl ring with electron withdrawing function (Cl,
NO2) the antibacterial behavior is decreased. When Ar is
unsubstituted phenyl ring the antibacterial activity is not
significant. It has also, been noticed that when Ar is pyri-
dine ring exhibited in (6p) and (6q) increase in the ob-
served antibacterial properties was noticed compared with
the case of using phenyl ring.
In vitro antifungal activity
With respect to antifungal activity, the synthesized com-
pounds were screened against three fungal strains;Table 1 Synthesis of the 2-arylidine-1-thia-4-
azaspiro[4.5]decan-3-ones (5a–f) using DBSNa (15 mol%)
Entry Producta Ar Time (min) Yieldb (%)
1 5a Ph 60 94
2 5b 4-ClC6H4 50 96
3 5c 4-BrC6H4 60 93
4 5d 4-O2NC6H4 45 87
5 5e 4-MeOC6H4 40 98
6 5f 4-pyridyl 70 90
a Reaction conditions: 1-thia-4-azaspiro[4.5]decan-3-one (3) (10 mmol), aromatic
aldehydes (4a-f) (10 mmol), and DBSNa (20 mol%) in 10 mL acetic acid at
room temperature.
b Isolated yields.Aspergillus niger, Candida albicans, Fusarium oxyspor-
ium using Nystatin as standard antifungal reference (at
50 mg/mL concentration). Most of the tested com-
pounds showed excellent antibacterial activities with re-
spect to the reference drug.
As antibacterial activity, the obtained results indicated
that the type of substituents (Ar) and (R) are the con-
trolling factors in developing the antifungal properties of
the tested compounds (6a-r). Results of antifungal activ-
ities were shown in Table 6. Data in Table 6 showed that
compounds 6d, 6 l, and 6p have remarkable antifungal
potency. Compounds 6 l [Ar = 4-O2NC6H4; R = piperi-
din-1-yl] exhibit excellent activities against Candida
albicans and Fusarium oxysporium as well as good po-
tency against Aspergillus niger. Compound 6p [Ar = 4-
pyridyl; R = piperidin-1-yl] has excellent activity against
Aspergillus niger as well as good potency against Can-
dida albicans and Fusarium oxysporium. Compound 6d
[Ar = 4-ClC6H4; R = piperidin-1-yl] exhibit good potency
against Aspergillus niger, Candida albicans and Fusar-
ium oxysporium. Structure-Activity relationships (SAR)
based on the obtained results indicated that the best ob-
served antifungal activity is that which Ar is phenyl ring
attached with electron withdrawing function (NO2, Cl)
as exhibit in compound 6l and 6d, respectively. How-
ever, substituting the phenyl ring with electron donating
function (MeO) the antifungal behavior is decreased.
When Ar is unsubstituted phenyl ring the antifungal ac-
tivity is not remarkable. It has also, been noticed that
when Ar is pyridine ring exhibited in (6p) increase in
the observed potent antifungal properties was noticed
compared with the case of using phenyl ring.
Conclusions
The authors have developed a novel, rapid and efficient
protocol for the synthesis of various 2-arylidine-1-thia-4-
azaspiro[4.5]decan-3-ones using sodium dodecylbenzene
sulfonate (DBSNa) in acetic acid at room temperature.
The results clearly demonstrate that the using of the so-
dium dodecylbenzene sulfonate as an inexpensive and
readily available reagent markedly enhances the efficiency
of the chemical processes of interest. Mannich bases from
the synthesized 2-arylidine-1-thia-4-azaspiro[4.5]decan-3-
ones were achieved and evaluated as antimicrobial agents
and showed remarkable activities.
Scheme 3 Synthesis of 2-benzylidine-1-thia-4-azaspiro[4.5]decan-3-ones (5a).
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General methods The time required for completion of
each reaction was monitored by TLC. All melting points
are uncorrected and were measured on a Gallenkamp
apparatus. The IR spectra were recorded on a Shimadzu
470 IR spectrometer (KBr) νmax, cm−1. The 1H and 13C
NMR spectra were measured on a Varian EM-200 (1H:
400 MHz, 13C: 100 MHz) spectrometer with TMS as in-
ternal standard. Mass spectra were determined on a
JEOL JMS-600 spectrometer. Elemental analyses (C, H,
N, and S) were performed on an elemental analysis sys-
tem GmbH VarioEL V2.3.General procedure for synthesis of 2-Arylidine-1-thia-4-
azaspiro[4.5]decan-3-ones (5a-f)
To a solution of (3) (1.71 g, 10 mmol) in acetic acid
(10 mL), corresponding aromatic aldehyde (10 mmol)
was added. Then DBSNa (20 mol%) was added and the
reaction mixture was stirred at room temperature for
the desired time as monitored by TLC (Table 1). After
completion of the reaction, the solid product was filtered
and washed with cold water, dried, and recrystallized
from ethanol (95%).Table 2 The effect of reaction condition on the synthesis
of (5a) under various conditionsa
Entry Solventb Catalystc Time (min) Yieldd (%)
1 EtOH Piperidine 180 37
2 EtOH AcOH 180 43
3 EtOH p-TSA 180 40
4 AcOH AcONa 150 46
5 AcOH H2SO4 120 61
6 EtOH DBSNa 120 66
7 MeOH DBSNa 120 64
8 AcOH DBSNa 60 94
9 H2O DBSNa 180 trace
a The reaction was carried out with 1-thia-4-azaspiro[4.5]decan-3-one (3)
(10 mmol), benzaldehydes (4a) (10 mmol) at room temperature.
b 10 mL solvent.
c 20 mol%.
d Isolated yields.2-Benzylidene-1-thia-4-azaspiro[4.5]decan-3-one (5a)
Pale yellow crystals; mp 200–202°C; IR: 3200 (NH), 3020
(CH arom.), 1700 (C =O), 695 (C-S); 1H NMR (DMSO-
d6): 1.10–1.95 (m, 10H, 5 × CH2), 7.50 (m, 5H, Ph-H),
7.85 (s, 1H, CH), 8.97 (s, 1H, NH, D2O-exchangeable)
ppm; 13C NMR: 21.7 (2 CH2), 24.8 (CH2), 25.6 (2CH2),
47.9 (spiro C), 122.3 (CH), 124.8 (2CH), 126.1 (2CH),
129.4 (C), 131.1 (C), 136.7 (C), 170.2 (C =O) ppm; EI-
MS, m/z (%): 260.10 (8) [M + 1], 259.01 (54) [M+],
216.05 (100.0). Calc. for C15H17NOS: C, 69.46; H, 6.61;




Pale yellow crystals; mp 210–212°C; IR: 3190 (NH), 3085
(CH arom.), 1695 (C =O), 695 (C-S); 1H NMR (DMSO-
d6): 1.15–2.10 (m, 10H, 5 × CH2), 7.35 (d, 2H, 2CH, J =
7.4), 8.00 (d, 2H, 2CH, J = 7.4), 8.90 (s, 2H, CH +NH)
ppm; EI-MS, m/z (%): 293.54 (44) [M+], 258.15 (30),
250.02 (100.0). Calc. for C15H16ClNOS: C, 61.32; H,
5.49; Cl, 12.07; N, 4.77; S, 10.91. Found: C, 61.12; H,
5.30; Cl, 11.88; N, 4.59; S, 10.78.
2-(4-Bromobenzylidene)-1-thia-4-azaspiro[4.5]decan-3-one
(5c))
Pale yellow crystals; mp 221–222°C; IR: 3200 (NH), 3090
(CH arom.), 1695 (C =O), 695 (C-S); 1H NMR (DMSO-
d6): 1.00–2.10 (m, 10H, 5 × CH2), 7.40 (d, 2H, 2CH, J =
7.2), 8.10 (d, 2H, 2CH, J = 7.2), 8.60 (s, 1H, CH), 10.10
(s, 1H, NH) ppm; EI-MS, m/z (%): 339.01 (20) [M+],
296.15 (100.0), 79 (15). Calc. for C15H16BrNOS: C,Table 3 Evaluation of catalytic activity of DBSNa in the
synthesis of (5a)a
Entry Amount of DBSNa (mol %) Time (min) Yieldb (%)
1 5 90 68
2 10 70 81
3 15 60 87
4 20 60 94
5 25 60 94
a The reaction was carried out with 1-thia-4-azaspiro[4.5]decan-3-one (3)
(10 mmol), benzaldehydes (4a) (10 mmol) and DBSNa in 10 mL acetic acid at
room temperature.
b Isolated yields.
Scheme 4 Synthesis of Mannich bases (6a-r).
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53.00; H, 4.80; Br, 23.47; N, 3.81; S, 9.19.2-(4-Nitrobenzylidene)-1-thia-4-azaspiro[4.5]decan-3-one
(5d))
Yellow crystals; mp 249–250°C; IR: 3220 (NH), 3090 (CH
arom.), 1690 (C =O), 690 (C-S); 1H NMR (DMSO-d6):
1.20–2.10 (m, 10H, 5 × CH2), 8.10 (d, 2H, 2CH, J = 7.4),
8.50 (d, 2H, 2CH, J = 7.4), 8.70 (s, 1H, CH), 10.20 (s, 1H,
NH) ppm; EI-MS, m/z (%): 304.61 (29) [M+], 261.25
(100.0). Calc. for C15H16N2O3S: C, 59.19; H, 5.30; N, 9.20;
S, 10.54. Found: C, 58.89; H, 5.43; N, 9.00; S, 10.30.Table 4 Synthesis of the Mannich bases (6a-r)a
Mannich product Ar R Time (h) Yieldb (%)
6a Ph piperidin-1-yl 2.0 80
6b Ph morphilin-1-yl 3.0 76
6c Ph pyrrolidin-1-yl 2.5 79
6d 4-ClC6H4 piperidin-1-yl 1.5 91
6e 4-ClC6H4 morphilin-1-yl 2.5 88
6f 4-ClC6H4 pyrrolidin-1-yl 2.0 80
6g 4-BrC6H4 piperidin-1-yl 2.0 81
6h 4-BrC6H4 morphilin-1-yl 2.0 80
6i 4-BrC6H4 pyrrolidin-1-yl 3.0 80
6j 4-O2NC6H4 piperidin-1-yl 3.0 76
6k 4-O2NC6H4 morphilin-1-yl 4.0 71
6l 4-O2NC6H4 pyrrolidin-1-yl 3.5 73
6m 4-MeOC6H4 piperidin-1-yl 1.5 89
6n 4-MeOC6H4 morphilin-1-yl 2.5 81
6o 4-MeOC6H4 pyrrolidin-1-yl 2.0 83
6p 4-pyridyl piperidin-1-yl 2.0 89
6q 4-pyridyl morphilin-1-yl 3.0 79
6r 4-pyridyl pyrrolidin-1-yl 2.0 82
a Reaction conditions: 2-arylidine-1-thia-4-azaspiro[4.5]decan-3-ones (5a-f)
(10 mmol), formaldehyde (15 mmol), and secondary amine (15 mmol) in
10 mL absolute ethanol at room temperature.
b Isolated yields.2-(4-Methylbenzylidene)-1-thia-4-azaspiro[4.5]decan-3-one
(5e))
Yellow crystals; mp 230–231°C; IR: 3200 (NH), 3090
(CH arom.), 1695 (C =O), 690 (C-S); 1H NMR (DMSO-
d6): 1.10–2.05 (m, 10H, 5 × CH2), 3.85 (s, 3H, CH3), 7.05
(d, 2H, 2CH, J = 7.3), 7.60 (d, 2H, 2CH, J = 7.3), 7.85 (s,
1H, CH), 8.90 (s, 1H, NH) ppm; 13C NMR: 22.2 (2 CH2),
24.7 (CH2), 26.1 (2CH2), 42.1 (CH3), 47.3 (spiro C),121.9
(CH), 125.3 (2CH), 126.7 (2CH), 129.2 (C), 131.5 (C),
136.9 (C), 171.3 (C = O) ppm; EI-MS, m/z (%): 290.54
(12) [M+ + 1], 289.02 (40) [M+], 274.01 (17), 246.12
(100.0). Calc. for C16H19NO2S: C, 66.41; H, 6.62; N,
4.84; S, 11.08. Found: C, 66.09; H, 6.45; N, 4.68; S, 10.85.
2-(Pyridin-4-ylmethylene)-1-thia-4-azaspiro[4.5]decan-3-
one (5f))
Pale yellow crystals; mp 225–227°C; IR: 3190 (NH), 3090
(CH arom.), 1695 (C =O), 695 (C-S); 1H NMR (DMSO-
d6): 1.05–2.10 (m, 10H, 5CH2), 7.00 (d, 2H, 2CH, J =
6.8), 7.70 (d, 2H, 2CH, J = 6.8), 7.80 (s, 1H, CH), 8.10 (s,
1H, NH) ppm; EI-MS, m/z (%):260.15 (25) [M+], 217.15
(100.0). Calc. for C14H16N2OS: C, 64.58; H, 6.19; N,
10.76; S, 12.32. Found: C, 64.36; H, 6.00; N, 10.79; S,
12.20.
General procedure for synthesis of Mannich Bases (6a-r))
To a solution of 2-benzylidene-1-thia-4-azaspiro[4.5]de-
can-3-one (5a) (0.259 g, 1 mmol) in 5 mL of absolute
ethanol was added a mixture of sec. amine (1.5 mmol)
and aqueous formaldehyde 35% (0.2 mL, 1.5 mmol) also
dissolved in 5 mL absolute ethanol. The reaction mix-
ture was stirred for the desired time as monitored by
TLC (Table 4), refrigerated for 24 h to form crystals.
The crystalline product was separated by filtration, vac-
uum dried and recrystallized from ethanol.
2-Benzylidene-4-(piperidin-1-ylmethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6a))
Pale yellow crystals; mp 119–120°C; IR: 3030 (CH
arom.), 2950 (CH aliph.), 1700 (C =O), 695 (C-S); 1H
NMR (CDCl3): 1.38–1.51 (m, 12H, 6CH2), 2.10-2.37 (m,
4H, 2CH2), 2.43-2.48 (m, 4H, 2CH2), 4.08 (s, 2H, CH2),
Table 5 Bactericidal activity of Mannich bases (6a-r) using Ciprofloxacin as standard antibacterial referencea
Compound Staphylococcus aureus Escherichia Coli Pseudomonas aeroginosa
6a – + –
6b ++ + ++
6c – – –
6d ++ + +
6e +++ +++ +++
6f – + –
6g + ++ –
6h ++ ++ ++++
6i – – +
6j ++ – –
6k + +++ ++
6l – – –
6m +++ +++ ++
6n ++++ ++++ +++
6o + + –
6p ++++ + ++
6q ++++ +++ +++
6r - ++ +
Ciprofloxacin ++++ ++++ ++++
a The activities are based on the diameter of zones of inhibition in mm. 50 μL of stock solution was applied in each hole of each paper disk. +: <15 mm; ++: 15–24 mm;
+++: 25–34 mm; ++++: 35–44 mm.
Table 6 Fungicidal activity of Mannich bases (6a-r) using Nystatin as standard antifungal referencea
Compound Aspergillus niger Candida albicans Fusarium oxysporium
6a + + +
6b + – +
6c – – –
6d +++ +++ +++
6e ++ +++ +
6f + ++ –
6g ++ ++ ++
6h + + –
6i – ++ –
6j ++ - +
6k ++ +++ ++
6l +++ ++++ ++++
6m ++ – –
6n + + ++
6o +++ ++ –
6p ++++ +++ +++
6q +++ ++ +++
6r + + +
Nystatin ++++ ++++ ++++
a The activities are based on the diameter of zones of inhibition in mm. 50 μL of stock solution was applied in each hole of each paper disk. +: <15 mm; ++: 15–24 mm;
+++: 25–34 mm; ++++: 35–44 mm.
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m/z (%): 357.05 (9) [M+ + 1], 356.01 (46) [M+], 258.12
(25), 215.65 (100.0). Calc. for C21H28N2OS: C, 70.75; H,
7.92; N, 7.86; S, 8.99. Found: C, 70.52; H, 7.80; N, 7.66;
S, 8.78.2-Benzylidene-4-(morpholinomethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6b))
Pale yellow crystals; mp 135–137°C; IR: 3020 (CH
arom.), 2955 (CH aliph.), 1700 (C =O), 695 (C-S); 1H
NMR (DMSO-d6): 1.42–1.51 (m, 6H, 3CH2), 2.15-2.40
(m, 4H, 2CH2), 2.47 (t, 4H, 2CH2, J = 6.9), 3.59 (t, 4H,
2CH2, J = 6.9), 4.15 (s, 2H, CH2), 7.33-7.61 (m, 5H, Ph-
H), 7.71 (s, 1H, CH) ppm; EI-MS, m/z (%): 359.01 (5)
[M+ + 1], 358.00 (32) [M+], 258.09 (17), 216.05 (100.0).
Calc. for C20H26N2O2S: C, 67.01; H, 7.31; N, 7.81; S,
8.94. Found: C, 66.80; H, 7.05; N, 7.65; S, 8.70.
2-Benzylidene-4-(pyrrolidin-1-ylmethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6c))
Yellow crystals; mp 126–127°C; IR: 3020 (CH arom.),
2880 (CH aliph.), 1705 (C = O), 695 (C-S); 1H NMR
(CDCl3): 1.43-1.52 (m, 6H, 3CH2), 1.62 (t, 4H, 2CH2, J =
7.1), 2.17-2.40 (m, 4H, 2CH2), 2.53 (t, 4H, 2CH2, J = 7.1),
4.01 (s, 2H, CH2), 7.30-7.58 (m, 5H, Ph-H), 7.60 (s, 1H,
CH) ppm; EI-MS, m/z (%): 341.82 (15) [M+], 258.09
(25), 215.85 (100.0). Calc. for C20H26N2OS: C, 70.14; H,




Yellow crystals; mp 120–122°C; IR: 3050 (CH arom.),
2955 (CH aliph.), 1700 (C = O), 695 (C-S); 1H NMR
(CDCl3): 1.44–1.61 (m, 12H, 6CH2), 2.10-2.46 (m, 8H,
4CH2), 4.25 (s, 2H, CH2), 7.40 (d, 2H, 2CH, J = 7.6), 7.60
(s, 1H, CH), 7.72 (d, 2H, 2CH, J = 7.6) ppm; EI-MS, m/z
(%): 390.65 (32) [M+], 292.12 (16), 215.05 (100.0). Calc.
for C21H27ClN2OS: C, 64.51; H, 6.96; Cl, 9.07; N, 7.17; S,
8.20. Found: C, 64.22; H, 6.66; Cl, 8.81; N, 7.00; S, 7.92.2-(4-Chlorobenzylidene)-4-(morpholinomethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6e))
Pale yellow crystals; mp 141–143°C; IR: 3050 (CH
arom.), 2880 (CH aliph.), 1700 (C =O), 695 (C-S); 1H
NMR (DMSO-d6): 1.44–1.56 (m, 6H, 3CH2), 2.18-2.45
(m, 4H, 2CH2), 2.52 (t, 4H, 2CH2, J = 7.8), 3.50 (t, 4H,
2CH2, J = 7.9), 4.23 (s, 2H, CH2), 7.38 (d, 2H, 2CH, J =
6.5), 7.64 (s, 1H, CH), 7.70 (d, 2H, 2CH, J = 6.5) ppm;
EI-MS, m/z (%): 392.71 (56) [M+], 292.00 (20), 216.65
(100.0). Calc. for C20H25ClN2O2S: C, 61.13; H, 6.41; Cl,9.02; N, 7.13; S, 8.16. Found: C, 60.86; H, 6.20; Cl, 8.80;
N, 6.90; S, 7.88.
2-(4-Chlorobenzylidene)-4-(pyrrolidin-1-ylmethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6f))
Pale yellow crystals; mp 133–135°C; IR: 3035 (CH
arom.), 2895 (CH aliph.), 1700 (C =O), 690 (C-S); 1H
NMR (CDCl3): 1.40-1.51 (m, 6H, 3CH2), 1.64 (t, 4H,
2CH2, J = 7.5), 2.25-2.38 (m, 4H, 2CH2), 2.62 (t, 4H,
2CH2, J = 7.5), 4.12 (s, 2H, CH2), 7.35 (d, 2H, 2CH, J =
6.3), 7.62 (d, 2H, 2CH, J = 6.3), 7.64 (s, 1H, CH) ppm;
EI-MS, m/z (%): 375.90 (18) [M+], 291.89 (30), 215.70
(100.0). Calc. for C20H25ClN2OS: C, 63.73; H, 6.68; Cl,
9.41; N, 7.43; S, 8.51. Found: C, 63.45; H, 6.70; Cl, 9.19;
N, 7.20; S, 8.27.
2-(4-Bromobenzylidene)-4-(piperidin-1-ylmethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6g))
Pale yellow crystals; mp 133–135°C; IR: 3050 (CH
arom.), 2940 (CH aliph.), 1705 (C =O), 690 (C-S); 1H
NMR (CDCl3): 1.38–1.50 (m, 12H, 6CH2), 2.05-2.47 (m,
8H, 4CH2), 4.05 (s, 2H, CH2), 7.31 (d, 2H, 2CH, J = 7.1),
7.58 (s, 1H, CH), 7.62 (d, 2H, 2CH, J = 7.1) ppm; EI-MS,
m/z (%): 436.15 (19) [M + 2], 434.09 (21) [M+], 335.60
(11), 216.95 (100.0). Calc. for C21H27BrN2OS: C, 57.93;
H, 6.25; Br, 18.35; N, 6.43; S, 7.36. Found: C, 57.68; H,
6.00; Br, 18.05; N, 6.22; S, 7.10.
2-(4-Bromobenzylidene)-4-(morpholinomethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6h))
Pale yellow crystals; mp 152–153°C; IR: 3030 (CH
arom.), 2850 (CH aliph.), 1705 (C =O), 695 (C-S); 1H
NMR (DMSO-d6): 1.40–1.53 (m, 6H, 3CH2), 2.10-2.40
(m, 4H, 2CH2), 2.52 (t, 4H, 2CH2, J = 6.9), 3.42 (t, 4H,
2CH2, J = 6.9), 4.09 (s, 2H, CH2), 7.35 (d, 2H, 2CH, J =
6.5), 7.65 (s, 1H, CH), 7.58 (d, 2H, 2CH, J = 6.5) ppm;
EI-MS, m/z (%): 438.01 (9) [M+ + 2], 436.2 (10) [M+],
336.20 (43), 216.75 (100.0). Calc. for C20H25BrN2O2S: C,
54.92; H, 5.76; Br, 18.27; N, 6.40; S, 7.33 Found: C,
54.75; H, 5.80; Br, 18.05; N, 6.17; S, 7.09.
2-(4-Bromobenzylidene)-4-(pyrrolidin-1-ylmethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6i))
Pale yellow crystals; mp 142–143°C; IR: 3040 (CH
arom.), 2890 (CH aliph.), 1700 (C =O), 695 (C-S); 1H
NMR (CDCl3): 1.41-1.50 (m, 6H, 3CH2), 1.60 (t, 4H,
2CH2, J = 7.1), 2.20-2.35 (m, 4H, 2CH2), 2.59 (t, 4H,
2CH2, J = 7.1), 4.10 (s, 2H, CH2), 7.33 (d, 2H, 2CH, J =
6.5), 7.47 (s, 1H, CH), 7.55 (d, 2H, 2CH, J = 6.5) ppm;
EI-MS, m/z (%): 420.96 (26) [M+], 335.89 (45), 216.71
(100.0). Calc. for C20H25BrN2OS: C, 57.00; H, 5.98; Br,
18.96; N, 6.65; S, 7.61. Found: C, 56.15; H, 5.69; Br,
18.80; N, 6.50; S, 7.57.
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azaspiro[4.5]decan-3-one (6j))
Yellow crystals; mp 142–144°C; IR: 3050 (CH arom.),
2900 (CH aliph.), 1700 (C = O), 690 (C-S); 1H NMR
(CDCl3): 1.45–1.61 (m, 12H, 6CH2), 2.17-2.49 (m, 8H,
4CH2), 4.26 (s, 2H, CH2), 7.92 (s, 1H, CH), 8.14 (d, 2H,
2CH, J = 6.8), 8.35 (d, 2H, 2CH, J = 6.8) ppm; EI-MS, m/z
(%): 402.16 (15) [M+ + 1], 303.62 (22), 215.85 (100.0).
Calc. for C21H27N3O3S: C, 62.82; H, 6.78; N, 10.47; S,
7.99. Found: C, 62.60; H, 6.57; N, 10.49; S, 7.76.
4-(Morpholinomethyl)-2-(4-nitrobenzylidene)-1-thia-4-
azaspiro[4.5]decan-3-one (6k))
Yellow crystals; mp 158–160°C; IR: 3020 (CH arom.),
2900 (CH aliph.), 1700 (C = O), 695 (C-S); 1H NMR
(DMSO-d6): 1.45–1.58 (m, 6H, 3CH2), 2.20-2.52 (m, 4H,
2CH2), 2.55 (t, 4H, 2CH2, J = 7.5), 3.54 (t, 4H, 2CH2, J =
7.5), 4.20 (s, 2H, CH2), 7.71 (s, 1H, CH), 8.08 (d, 2H,
2CH, J = 6.8), 8.29 (d, 2H, 2CH, J = 6.8) ppm; EI-MS, m/z
(%): 403.12 (41) [M+], 303.25 (35), 215.36 (100.0). Calc.
for C20H25N3O4S: C, 59.53; H, 6.25; N, 10.41; S, 7.95.
Found: C, 59.58; H, 6.01; N, 10.26; S, 7.71.
2-(4-Nitrobenzylidene)-4-(pyrrolidin-1-ylmethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6l))
Yellow crystals; mp 149–151°C; IR: 3025 (CH arom.),
2990 (CH aliph.), 1705 (C = O), 690 (C-S); 1H NMR
(CDCl3): 1.43-1.52 (m, 6H, 3CH2), 1.61 (t, 4H, 2CH2, J =
6.9), 2.25-2.37 (m, 4H, 2CH2), 2.58 (t, 4H, 2CH2, J = 6.9),
4.20 (s, 2H, CH2), 7.41 (s, 1H, CH), 7.93 (d, 2H, 2CH, J
= 6.8), 8.21 (d, 2H, 2CH, J = 6.8) ppm; EI-MS, m/z (%):
387.20 (19) [M+], 303.10 (44), 215.87 (100.0). Calc. for
C20H25N3O3S: C, 61.99; H, 6.50; N, 10.84; S, 8.27.
Found: C, 62.05; H, 6.24; N, 10.70; S, 8.00.
2-(4-Methoxybenzylidene)-4-(piperidin-1-ylmethyl)-1-thia-
4-azaspiro[4.5]decan-3-one (6m))
Pale yellow crystals; mp 121–123°C; IR: 3200 (NH), 3090
(CH arom.), 1700 (C =O), 690 (C-S); 1H NMR (CDCl3):
1.42–1.53 (m, 12H, 6CH2), 2.15-2.41 (m, 8H, 4CH2),
3.50 (s, 3H, CH3), 4.10 (s, 2H, CH2), 6.92 (d, 2H, 2CH, J
= 6.8), 7.45 (d, 2H, 2CH, J = 6.8), 7.56 (s, 1H, CH) ppm;
EI-MS, m/z (%): 386.20 (15) [M+], 288 (45), 216.05
(100.0). Calc. for C22H30N2O2S: C, 68.36; H, 7.82; N,
7.25; S, 8.30. Found: C, 68.39; H, 7.70; N, 7.00; S, 8.02.
2-(4-Methoxybenzylidene)-4-(morpholinomethyl)-1-thia-4-
azaspiro[4.5]decan-3-one (6n))
Pale yellow crystals; mp 133–135°C; IR: 3050 (CH
arom.), 2950 (CH aliph.), 1700 (C =O), 695 (C-S); 1H
NMR (CDCl3): 1.41–1.52 (m, 6H, 3CH2), 2.15-2.46 (m,
4H, 2CH2), 2.51 (t, 4H, 2CH2, J = 7.1), 3.50 (t, 4H, 2CH2,
J = 7.1), 4.08 (s, 2H, CH2), 7.01 (d, 2H, 2CH, J = 6.9), 7.60
(d, 2H, 2CH, J = 6.9), 7.69 (s, 1H, CH) ppm; EI-MS, m/z(%): 388.19 (20) [M+], 288.75 (51), 215.06 (100.0). Calc.
for C21H28N2O3S: C, 64.92; H, 7.26; N, 7.21; S, 8.25.
Found: C, 64.70; H, 7.00; N, 7.30; S, 8.01.2-(4-Methoxybenzylidene)-4-(pyrrolidin-1-ylmethyl)-1-thia-
4-azaspiro[4.5]decan-3-one (6o))
Yellow crystals; mp 140–142°C; IR: 3050 (CH arom.),
2900 (CH aliph.), 1700 (C = O), 695 (C-S); 1H NMR
(CDCl3): 1.40-1.49 (m, 6H, 3CH2), 1.60 (t, 4H, 2CH2),
2.20-2.32 (m, 4H, 2CH2), 2.55 (t, 4H, 2CH2, J = 7.3), 4.15
(s, 2H, CH2, J = 7.3), 7.01 (d, 2H, 2CH, J = 6.8), 7.26 (d,
2H, 2CH, J = 6.8), 7.29 (s, 1H, CH) ppm; EI-MS, m/z (%):
372.19 (32) [M+], 289.02 (35), 215.97 (100.0). Calc. for
C21H28N2O2S: C, 67.71; H, 7.58; N, 7.52; S, 8.61. Found:
C, 67.58; H, 7.60; N, 7.40; S, 8.45.4-(Piperidin-1-ylmethyl)-2-(pyridin-4-ylmethylene)-1-thia-
4-azaspiro[4.5]decan-3-one (6p))
Pale yellow crystals; mp 111–113°C; IR: 3050 (CH
arom.), 1695 (C =O), 690 (C-S); 1H NMR (CDCl3):
1.40–1.56 (m, 12H, 6CH2), 2.01-2.55 (m, 8H, 4CH2),
4.00 (s, 2H, CH2), 7.05 (d, 2H, 2CH, J = 6.9), 7.30 (s, 1H,
CH), 7.83 (d, 2H, 2CH, J = 6.9), ppm; EI-MS, m/z (%):
357.15 (16) [M+], 259.30 (40), 217.15 (100.0). Calc. for
C20H27N3OS: C, 67.19; H, 7.61; N, 11.75; S, 8.97. Found:
C, 67.25; H, 7.50; N, 11.80; S, 8.66.4-(Morpholinomethyl)-2-(pyridin-4-ylmethylene)-1-thia-4-
azaspiro[4.5]decan-3-one (6q))
Pale yellow crystals; mp 125–127°C; IR: 3050 (CH
arom.), 1700 (C =O), 695 (C-S); 1H NMR (CDCl3):
1.39–1.50 (m, 6H, 3CH2), 2.15-2.45 (m, 4H, 2CH2), 2.52
(t, 4H, 2CH2, J = 7.1), 3.47 (t, 4H, 2CH2, J = 7.1), 4.10 (s,
2H, CH2), 6.91 (d, 2H, 2CH, J = 6.9), 7.15 (s, 1H, CH),
7.80 (d, 2H, 2CH, J = 6.9) ppm; EI-MS, m/z (%): 359.60
(21) [M+], 259.95 (61), 216.95 (100.0). Calc. for
C19H25N3O2S: C, 63.48; H, 7.01; N, 11.69; S, 8.92.
Found: C, 63.20; H, 6.85; N, 11.71; S, 8.70.2-(Pyridin-4-ylmethylene)-4-(pyrrolidin-1-ylmethyl)-1-thia-
4-azaspiro[4.5]decan-3-one (6r))
Pale yellow crystals; mp 119–120°C; IR: 3050 (CH
arom.), 1695 (C = O), 690 (C-S); 1H NMR (CDCl3): 1.40-
1.49 (m, 6H, 3CH2), 1.59 (t, 4H, 2CH2, J = 7.2), 2.22-2.40
(m, 4H, 2CH2), 2.55 (t, 4H, 2CH2, J = 7.2), 4.08 (s, 2H,
CH2), 6.98 (d, 2H, 2CH, J = 6.4), 7.20 (s, 1H, CH), 7.90
(d, 2H, 2CH, J = 6.4) ppm; EI-MS, m/z (%): 343.05 (20)
[M+], 259.02 (65), 216.65 (100.0). Calc. for C19H25N3OS:
C, 66.44; H, 7.34; N, 12.23; S, 9.34. Found: C, 66.50; H,
7.36; N, 12.00; S, 9.16.
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Antibacterial activity
The newly synthesized compounds were screened for
their antibacterial activity against bacterial isolate namely
Staphylococcus aureus (ATCC 29213) as Gram positive
bacteria, Escherichia Coli (ATCC 25922), Pseudomonas
aeroginosa (ATCC 27953) as Gram negative bacteria by
cup-plate method [23]. The sterilized nutrient agar
medium was distributed 100 ml each in two 250 ml con-
ical flasks and allowed to cool to room temperature. To
these media, 18–24 h grown bacterial subcultures were
added and shaken thoroughly to ensure uniform distri-
bution of organism throughout the medium. Then, this
agar medium was distributed in equal portions, in steril-
ized Petri dishes, ensuring that each Petri dish contains
about 20 ml of the medium. The medium was then
allowed for solidification. Then, cups were made with
the help of a sterile cork borer (6 mm diameter) punch-
ing into the set of agar media.
The solutions of required concentration (50 μg/mL) of
test compounds were prepared by dissolving the com-
pounds in DMSO were filled into the cups with 1 mL of
respective solution. Then, the Petri dishes were kept for
incubation in an inverted position for 24–48 h at 37°C
in an incubator. When growth inhibition zones were de-
veloped surrounding each cup, their diameter in cm was
measured and compared with that of the Ciprofloxacin.Antifungal activity
The newly synthesized compounds were screened for
their antifungal activity against three fungal strains; As-
pergillus niger, Candida albicans, Fusarium oxysporium
at the concentration levels of 50 μg/mL by cup-plate
method, using Nystatin as the standard. To the sterilized
potato dextrose agar medium incubated for 72 h, subcul-
ture of fungus were added and shaken thoroughly to en-
sure uniform distribution. Then, this was poured into
previously sterilized and labeled Petri dishes and allowed
to solidify. Then, with the help of a borer four cups were
made in each plate. Two cups were filled with 0.1 ml of
two test dilutions and the other two cups with respective
concentrations of standard dilutions. Then, the plates
were left as it is for 2–3 h for diffusion and then they
were kept for incubation at 37°C for 24 h. Then the
diameter of the zones of growth inhibition was measured
and compared with that of standard.
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